

--with monocytes and lymphocytes--

IN THE CLAIMS

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

10. (Amended) The reagent according to any claim 2, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

20. (Amended) The method according to claim 12, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

31. (Amended) The diagnostic agent according to claim 23, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

42. (Amended) The diagnostic method according to claim 34, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

53. (Amended) The inhibitor of migration of a monocyte and/or a macrophage according to claim 45, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

65. (Amended) The therapeutic agent according to claim 57, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.